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ABSTRACT 
Skeletal muscles are a tissue with remarkable adaptability and are essential in the body in 
many aspects. The homeostasis of the muscles is vital for the maintenance of the body, thus 
muscle damage is associated with several diseases and leads to a poor quality of life. 
Acquired muscle weaknesses in the intensive care unit (ICU) is a major complication that 
occurs in severely ill patients and has a significant impact on the immune system, energy 
metabolism, amino acid reserves and temperature regulation in the body. Critical illness 
myopathy (CIM) is a myopathy that results from critical illness and is commonly found in 
mechanically ventilated ICU patients. It is characterized by paralysis of the limb muscles, 
atrophy and reduced muscle excitability. The exact cause and underlying mechanisms of the 
disease remain obscure, hence, the aim of this thesis was to achieve a better understanding of 
the cellular and molecular mechanisms underlying the muscle wasting and weakness seen in 
ICU patients with CIM. In accordance with this, a rodent ICU model was used to address the 
mechanistic and therapeutic aspects of the disease. This thesis has investigated the 
intracellular pathways controlling the mechanisms underlying muscle wasting in an ICU rat 
model and the effects of passive mechanical loading. Passive mechanical loading induced 
significant positive effects on muscle function in the limb muscles and was able to attenuate 
myosin protein loss, associated with mechanical silencing and CIM. It was also demonstrated 
that both fission and fusion events as well as mitophagy are significantly affected by 
mechanosensing. Mitochondria dynamic alterations induced by mechanical silencing were 
completely counteracted by passive mechanical loading. Additionally it is demonstrated that 
the temporal pattern and the lack of preferential myosin loss observed in the diaphragm in 
response to CMV and immobilization differs dramatically to what is occurring in the limb 
muscles. Further, the response of cranial nerve innervated masseter is also different from that 
of limb and diaphragm muscles. Early activation of heat shock proteins suggest that an 
enriched antioxidative profile in the masseter may play a role in the mechanism of preserved 
masticatory function in CIM. 
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1.1 SKELETAL MUSCLES 
Skeletal muscles are a tissue with remarkable adaptability essential in the body in many 
aspects. Skeletal muscles are not only important for generating force and movements but they 
also functions as an amino acid pool, helps to regulate body temperature, work as passive 
protectors of the bones and are important producers of cytokines and growth factors. All 
muscles have a common structure that gives them shape and organization. The major 
cytoskeletal structure for muscle contraction is the myofibril, which docks the actin (thin) and 
myosin (thick) filaments. A myofibril consists of numerous sarcomeres, which are the main 
contractile components. The sarcomeres are connected in tandem with each segment lined by 
the Z-disc, a macromolecular complex that consists of several scaffolding proteins. Each fiber 
has a complex arrangement that enables its specific functions such as contraction, metabolic 
properties and protein synthesis regulation. Within the muscles, there is a vascular network 
that allows the muscle fibers to obtain oxygen, energy substrates and dispose heat. This 
network helps the muscles to maintain a constant environment in the close surroundings of 
each muscle fiber during rest and also helps to minimize disturbance of the homeostasis in 
response to different stimuli e.g. environmental factors, nutrition, loading conditions, and 
contractile activity during exercise. The homeostasis of the muscle is vital for the 
maintenance of several essential functions, like breathing, body movements and speaking, 
which are crucial for personal independence. On the contrary, when the homeostasis is 
perturbed, it leads to muscle damage associated with several diseases and leads to a poor 
quality of life.  
 
1.1.1 Contractile proteins 
1.1.1.1 Myosin  
Myosin is a superfamily of molecular motor proteins that power muscle contraction, 
movement and load-dependent anchoring on actin filament in eukaryotic cells. Skeletal 
muscle myosin belongs to myosin class II and is the motor protein of the sarcomere. Myosin 
generates muscle contraction by transducing chemical energy into mechanical energy through 
ATPase activity in order to move along the actin filaments (Baldwin and Haddad, 2002; 
Sweeney and Houdusse, 2010). 
The myosin molecule consists of two globular domains (heads) and a long tail or rod. The 
head domain contains both ATP- and actin-binding sites and is able to hydrolyze ATP to 
generate force and movement. The C-terminal region of the two myosin heavy chains 
(MyHC) forms the α-helical coiled coil that constitutes the rod region of the myosin 
molecule. The myosin rods create the “thick” or myosin filament decorated with hundreds of 
myosin heads responsible for force generation and movement. 
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Different fiber types differ in their structural and metabolic properties as different muscles 
have varied requirements. The fiber types are divergent in their contractile speed and are 
usually classified with regard to the MyHC isoform into one slow and three fast types of 
muscle fibers. The mechanical and energetic aspects of slow fibers make them more suitable 
for low-intensity and long-lasting activity. Fast fibers, on the other hand are preeminent for 
short and strong contractile performances. In both cases, stability is required between the 
characteristics of the molecular motors and the metabolic processes aimed to ATP restoration. 
There are a number of MyHC isoforms. Type I fibers (slow) contain the MyHC1 isoform and 
the fast types IIA, IIX and IIB (fastest) contain MyHC-IIa, MyHC-type IIx and MyHC-IIb 
respectively (Pette and Staron, 2001; Schiaffino and Reggiani, 2011).  
1.1.1.2 Actin 
Myosin would not be a motor without its interaction with actin filaments (Sweeney and 
Houdusse, 2010). Actin is an abundant protein and highly evolutionarily conserved. The 
human genome has six actin genes that encode six functional actin isoforms that are 
expressed in serval muscle and non-muscle tissues. The most important are the ACTA1- and 
ACTC1- genes encoding skeletal muscle α-actin and its cardiac counterpart, cardiac muscle α-
actin (Perrin and Ervasti, 2010; Tondeleir et al., 2009). The actin protein is composed of a 
single polypeptide chain of 375 amino acids, containing 4 subdomains in a double helical 
structure. In eukaryotic cells actin exists in two forms, globular actin (G-actin) and 
filamentous actin (F-actin). 
 
1.2 REGULATION OF MUSCLE MASS 
Skeletal muscle mass is ultimately determined by the balance between the rate of protein 
synthesis and protein degradation (Goodman et al., 2011). How skeletal muscles respond to a 
certain stimuli is controlled by two conflicting events, muscle growth and muscle 
degradation. These two activities are mechanistically linked with a common set of molecules 
controlling cellular pathways that regulate how the muscle will respond; with increased 
protein synthesis and stimulation of cell growth (muscle hypertrophy) or with increased 
protein breakdown and reduced cell growth (muscle atrophy) (Sartorelli and Fulco, 2004). 
Regulation of muscle mass is hence a coordinated balance between protein degradation and 
synthesis that reflects the physiological state of the muscle fiber. Hypertrophy occurs during 
development, in response to mechanical overload or anabolic hormonal stimulation. In 
contrast, muscle atrophy occurs in response to aging, starvation, cancer, diabetes, bed rest, 
denervation or catabolic hormonal stimulation (Schiaffino et al., 2013). Additionally, fiber 
cross-sectional area (CSA), is a particularly adaptive and important property of skeletal 
muscles that undergoes continuous modification to regulate muscle strength and metabolism 
(Bodine and Baehr, 2014).  
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1.2.1 Skeletal muscle growth (muscle protein synthesis) 
Skeletal muscles have a remarkable ability to adapt and previous studies have shown that 
various stimuli such as nutrients, growth factors, and mechanical load, can regulate protein 
synthesis in skeletal muscles (Horiba et al., 2015; Kimball et al., 2002; Raskin et al., 2009; 
Wong and Booth, 1985). This regulation is mainly controlled at the level of translational 
initiation rather than the result of an increase in RNA content (Kimball and Jefferson, 2010; 
Laurent et al., 1978), the regulation of stimuli effect is primarily controlled by the protein 
kinase mammalian (or mechanistic) target of rapamycin (mTOR).  
1.2.1.1 mTOR 
mTOR occurs in two complexes; mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC1 is the rapamycin sensitive complex that consist of the regulatory 
associated protein of mTOR (RAPTOR), mammalian lethal with SEC13 protein 8 (mLST8; 
a.k.a. GbL), the Dep domain-containing mTOR-interacting protein (DEPTOR) and the 
proline-rich Akt substrate of 40 kDa (PRAS40). In contrast, mTORC2 is the rapamycin-
insensitive complex, composed of the rapamycin insensitive companion of mTOR 
(RICTOR), mLST8, DEPTOR, stress-activated protein kinase-interacting protein 1 (mSIN1) 
and the protein observed with RICTOR (PROTOR) (Weigl, 2012).  
Several studies have shown that signaling by mTORC1, regulates initiation of translation 
through the phosphorylation of substrates such as eukaryotic initiation factor (eIF), 4E 
binding protein-1 (4EBP-1), ribosomal protein S6 (S6) and p70 ribosomal protein S6 kinase 
(S6K) (Baar and Esser, 1999; Haghighat et al., 1995; Hara et al., 1997; Heitman et al., 1991). 
These substrates are key regulators of protein synthesis, and are expressed in all cell types 
(Weigl, 2012). The efficiency of an mRNA is mainly controlled by the eukaryotic initiation 
factor 4E (eIF4E) which is also part of the eIF4F-complex, together with eIF4G and eIF4A. 
eIF4A is an RNA helicase which is able to unwind hairpin structures in the 5´untranslated 
region (UTR) of mRNAs, hence promoting the translational process (Ray et al., 1983; Rogers 
et al., 2001). 4E-BP1 is an inhibitory phospho-protein, that in the hypo-phosphorylated state, 
is bound to eIF4E and thereby hindering the association of the eIF4F-complex (Figure 1). 
When mTOR phosphorylates 4EBP-1, 4EBP-1 detaches from eIF4E and increases the 
formation of the eIF4F complex and can drastically improve the protein synthesis rate 
(Weigl, 2012). S6K1 is a positive regulator of protein translation initiation. mTOR 
phosphorylates S6K which in turn phosphorylates several other proteins that also affect 
translation initiation like S6 and eIF4B, another member of the initiation eIF4F-complex 
(Marina et al., 2005). Thus, the control of translation initiation by mTOR is key for the 
regulation of protein synthesis in skeletal muscles (You et al., 2015).  
The upstream regulators of mTOR are linked with growth factors, nutrients, energy and stress 
(Figure 1). Growth factors like insulin and IGFs stimulates phosphoinositide 3 kinase 
(PI3K), which leads to the activation of Akt (Aka. protein kinase B, PKB). Activated Akt 
phosphorylates the tuberous sclerosis complex 2 (TSC2) which is a protein that forms the 
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TSC1/2 complex, together with TSC1 (Inoki et al., 2002). Phosphorylation of TSC2, by Akt, 
prevent its inhibition of Rheb from promoting mTORC1 activity (Stocker et al., 2003; Weigl, 
2012). In addition to Akt, mTOR responds to many upstream signals, including amino acids. 
Further, mTOR controls several cellular processes in addition to protein synthesis such as 
autophagy (Sandri, 2010). It has been shown that rapamycin can inhibit mechanically induced 
growth and mechanically induced changes in protein synthesis in skeletal muscles 
(Hornberger et al., 2007; Kubica et al., 2005), this together with studies with transgenic mice 
models of mTORC1 inactivation indicate that mechanical stimulation of skeletal muscles is 
sufficient to activate mTORC1, and that the activation of mTORC1 is the basis for the 




Figure 1.  mTORC1 Signaling 
Simplified map of the mTORC1 signaling pathway. Numerous cellular signals associated by the mTORC1 to 
regulate cell proliferation and growth (Weigl, 2012). With permission from Elsevier. 
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1.2.1.2 Myostatin-Smad2/Smad3 pathway 
Smad signaling can be activated by the transforming growth factor-β (TGFβ) superfamily of 
receptor ligand proteins, with Myostatin (Mstn) being their most famous member. 
Additionally Smad signaling can also be activated by activins, some growth differentiation 
factors (GDF) and also bone morphogenic proteins (BMPs) (Miyazono et al., 2005; 
Moustakas and Heldin, 2009). Regulation of muscle mass by Smad signaling was initially 
discovered by the finding that inhibition of the Mstn (Aka., GDF-8) gene and of Mstn 
receptor binding, resulted in prominent skeletal muscle hypertrophy (Lee and McPherron, 
2001; McPherron et al., 1997). Later it was shown that an increase in Mstn is associated with 
skeletal muscle atrophy (Gonzalez-Cadavid et al., 1998; Zimmers et al., 2002). Hence, Mstn 
has proven to be a negative regulator of skeletal muscle mass, in part via Smad signaling 
(Goodman and Hornberger, 2014; Sartori and Sandri, 2015; Sartori et al., 2013). Mstn-
mediated Smad signaling is activated when the Mstn peptide binds activin type IIB and type 
IIA receptors (ActRIIB/IIA). This activation leads to the activation of activin receptor-like 
kinase-4 and -5 (ALK4 and ALK5), that in turn phosphorylates Smad 2 and 3 (Ross and Hill, 
2008). These transcription factors can then form a complex with another Smad2 or 3 
molecule, and additionally a Smad 4. This will result in the translocation of the complex to 
the nucleus where it regulates gene transcription.(Ross and Hill, 2008; Tsuchida et al., 2008; 
Walton et al., 2012). 
Sartori et al (Sartori et al., 2009), first demonstrated that Smad signaling is essential in 
Mstn/activin/ TGF-β-induced muscle atrophy. It was demonstrated that overexpression of a 
constitutively active mutant of ALK5, up-regulated atrogin-1 and induced muscle fiber 
atrophy via a Smad3 (Sartori et al., 2009). It was also demonstrated that an increase in Mstn 
is enough to prompt a decrease in protein synthesis and a possible mechanisms for this is by 
atrogin-1 degradation or via the inhibition of signaling through the Akt and mTORC1, or 
both (Amirouche et al., 2009; Lagirand-Cantaloube et al., 2008; Lokireddy et al., 2011; 
Sartori and Sandri, 2015; Trendelenburg et al., 2009).   
1.2.1.3 Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α)  
Peroxisome proliferator-activated receptors γ (PPARγ) coactivator-1α (PGC-1α) is a 
metabolic transcription co-activator in mammals. PGC-1α is activated by signals that control 
energy and nutrients in the cell. Specifically, PGC-1α induces and coordinates gene 
expression that stimulates mitochondrial biogenesis, fiber-type switching in skeletal muscles, 
and metabolic pathways linked to the fasted response in the liver (Puigserver, 2005). The 
expression of PGC-1α in skeletal muscles is greatly influenced by levels of physical activity, 
with endurance exercise increasing PGC-1α expression and physical inactivity leading to 
decreased expression (Aoi et al., 2010; Correia et al., 2015; Pilegaard et al., 2003; Scarpulla, 
2008). Several studies have shown that PGC-1α expression decreases in muscle wasting 
(Adhihetty et al., 1985; Baker et al., 2006; Ling et al., 2004; Roberts-Wilson et al., 2010; 
Sainz et al., 2009), but there are also models that have shown the contrary, an increase in 
PGC-1α expression (Abruzzo et al., 2010; Sainz et al., 2009; Wagatsuma et al., 2011). So far 
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no one has shown that the loss of PGC-1α expression per se is sufficient to induce muscle 
atrophy. However, it has been confirmed that an increased expression of PGC-1α is sufficient 
to mitigate protein degradation and protect skeletal muscle mass from different atrophic 
stimuli (Cannavino et al., 2014; Goodman et al., 2011) 
 
1.2.2 Skeletal muscle atrophy (muscle protein degradation) 
The loss of skeletal muscle mass is a complex process that occurs as a consequence of a 
variety of stressors. Atrophy includes the reduction of muscle fibers CSA due to a net loss of 
proteins, organelles and cytoplasm. This occurs as a result of alterations in the balance 
between anabolic and catabolic processes, with the net result being a loss of muscle mass 
when protein breakdown exceeds protein synthesis (Bodine and Baehr, 2014). Acute muscle 
atrophy occurs in many pathological conditions, including neural inactivity, mechanical 
unloading, inflammation, metabolic stress, and elevated glucocorticoids levels. Acute muscle 
atrophy is then due to hyper-activation of the main cellular degradation pathways like 
ubiquitin-proteasome system (UPS) and the autophagy lysosome pathways (Sandri, 2013; 
Schiaffino et al., 2013). The activation of proteolytic systems in the cells is regulated at the 
gene level and the transcripts associated with muscle atrophy have been studied by gene 
expression profiling (Gomes et al., 2001; Bodine et al., 2001a). A subset of genes that are 
commonly up- or down- regulated in muscle atrophy, irrespective of the underlying cause,  
have been identified and are called atrophy-related genes or “atrogenes” (Bodine et al., 2001; 
Gomes et al., 2001; Lecker et al., 2004; Sacheck et al., 2007). Among these atrogenes there 
are several transcripts associated with the UPS and autophagy (Sandri, 2008). 
Atrogenes as well as protein breakdown in general, are blocked by the IGF1/Akt pathway. 
Akt phosphorylates Forkhead Box (Fox) O, thus inhibiting the UPS. In times of food 
deprivation when insulin levels are low, muscle mass is reduced by protein degradation, 
whereas high nutritional supply leads to a blockade of protein degradation and increased 
protein synthesis by activation of mTORC1. Members of the FoxO family (FoxO1, 3 and 4), 
downstream Akt, have been identified as key transcription factors controlling the expression 
of MuRF1 and atrogin-1. Additionally it has been shown that FoxO3, specifically, also 
regulates autophagy (Mammucari et al., 2007; Sandri et al., 2004; Zhao et al., 2007). Recent 
work by Milan et al. (Milan et al., 2015) demonstrates that muscle-specific deletion of FoxO 
members protects the muscle from atrophy, further demonstrating the role of FoxOs in the 
induction of the UPS and the autophagy lysosome pathway. Furthermore, it was 
demonstrated that FoxOs control several stress-response pathways such as the unfolded 
protein response, ROS detoxification, DNA repair and translation (Milan et al., 2015).  
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1.2.2.1 Ubiquitin proteasome system 
The UPS is an ATP-dependent proteolytic system that targets proteins with ubiquitin (Ub) 
molecule substrates, through a cascade of conjugating enzymes (ligases), for identification of 
degradation (Murton et al., 2008). The ubiquitin ligase enzymes (E3), binds the protein 
substrate and once a protein is ubiquitinated, it is unfolded and fed into the proteasome in an 
ATP-dependent process. (Sandri, 2013). Two important atrogenes that have been found in 
several animal models of muscle atrophy including burn injury, diabetes, denervation, 
unloading, dexamethasone administration, and sepsis, are muscle-specific E3s; atrogin-1 and 
muscle RING finger-1 (MuRF1) (Kisselev and Goldberg, 2001). These two atrogenes have 
been extensively studied in muscle protein degradation and their involvement in muscle 
atrophy is well known. Mice lacking atrogin-1 and MuRF1 are resistant to muscle atrophy in 
response to denervation and knockdown of atrogin-1 prevents muscle wasting induced by 
fasting (Bodine et al., 2001; Cong et al., 2011).   
It has been shown that MuRF1 interacts with and controls the half-life of several essential 
muscle structural proteins like troponin I (Kedar et al., 2004), MyHC (Clarke et al., 2007; 
Fielitz et al., 2007) and actin (Polge et al., 2011). So far only a few muscle proteins have been 
identified as substrates for atrogin-1. The substrates found are however all related to growth-
associated processes (Csibi et al., 2010; Tintignac et al., 2005). Even though MuRF1 and 
atrogin-1 are significant Ub-ligases involved in muscle atrophy, there are likely to be other 
E3s related to muscle wasting. Additionally, particular Ub ligases can be involved in different 
muscle atrophy models and in different stages of the process. Recently a new set of Ub 
ligases have been discovered as significant atrogenes that are under the control of the FoxO-
family. This set of  Ub-ligases includes MUSA1, an E3, that has been found to be critical in 
muscle atrophy during denervation and fasting (Sartori et al., 2013), Fbxo31, an additional 
E3, Itch, a Ub-ligase that regulates the half-life of several transcription factors, and Fbxo21, a 
gene of unknown function but that contains an F-box motif and that has been given the name 
SMART (Specific of muscle atrophy and regulated by transcription). This novel set of E3s 
were all up-regulated in response to denervation induced atrophy (Milan et al., 2015).  
1.2.2.2 Autophagy lysosome pathway 
Autophagy is a physiological process that is vital for the cells to eliminate damaged cell-
components and to remodel the cellular architecture (Neel et al., 2013). There are three types 
of autophagy that all promote proteolytic degradation of cytosolic components; macro-
autophagy, micro-autophagy and chaperone mediated autophagy (CMA). Both macro-and 
micro-autophagy can ingest large structures through selective and non-selective mechanisms. 
Macro-autophagy transports cytoplasmic cargo to the lysosome through the intermediate of 
an autophagosome, a double membrane-bound vesicle. The autophagosome will then fuse 
with the lysosome forming an autolysosome. In contrast, in micro-autophagy, the cytosolic 
components are taken up by the lysosome directly through invagination of the lysosomal 
membrane (Glick et al.; Sandri, 2010). In the third type of autophagy CMA, proteins that 
have been targeted are translocated in a complex with chaperone proteins (such as heat shock 
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proteins), and can cross the lysosomal membrane. This way the targeted proteins can be 
recognized by the lysosomal membrane receptor, lysosomal-associated membrane protein 2A 
(LAMP-2A) and are subsequently unfolded and degraded (Saftig et al., 2008).  
Autophagy is primarily considered to be a non-selective degradation pathway, but autophagy 
can trigger the selective elimination of specific organelles, such as mitochondria (via 
mitophagy). Parkin, PINK1, Bnip3 and Bnip3L are genes that have been identified in 
mammals to control mitophagy, inactivation of the genes encoding these proteins leads to 
abnormal mitochondria (Hara et al., 2006). During muscle wasting the mitochondrial network 
is drastically remodeled in response to fasting or denervation, and autophagy plays a great 
part in this process (Romanello et al., 2010a; Romanello and Sandri, 2010). Alteration in 
mitochondrial dynamics is sufficient to cause muscle wasting in mice, indicating that 
disturbance of the mitochondrial network is essential for the muscle homeostasis (Romanello 
et al., 2010a; Romanello and Sandri, 2010). The critical role of the autophagy-lysosome 
system in skeletal muscles has repeatedly been confirmed by showing that alterations to the 
system contribute to the pathogenesis of several genetic muscle diseases (Chang et al., 2012; 
Masiero et al., 2009; Raben et al., 2008). Autophagy has two important roles in muscle 
homeostasis; it can be harmful and trigger muscle degeneration, but it can also work as a 
compensatory mechanism for cell survival (Bonaldo and Sandri, 2013). 
1.2.2.3 Inflammatory cytokines 
NF-κB is a known regulator of genes that encode cytokines, cytokine receptors, and cell-
adhesion molecules. They all play major roles as mediators of immunity and inflammation 
and are also expressed in skeletal muscles. Tumor necrosis factor-α (TNFα) is an important 
cytokine involved in muscle wasting and cachexia (Peterson et al., 2011). When NF-κB is 
inactive, it is retained in the cytoplasm by IκB, a family of inhibitory proteins. However in 
response to TNFα, the IκB kinase (IKKβ) complex phosphorylates IκB, which results in the  
ubiquitination and degradation of the inhibitory protein, hence leading to the nuclear 
translocation of NF-κB and activation of NF-κB-mediated gene transcription (Bonaldo and 
Sandri, 2013; Peterson et al., 2011). NF-κB regulates the transcription of more than 400 
genes that are involved in immune- and growth-regulation, inflammation, carcinogenesis, and 
apoptosis (Carmeli et al., 2015). Additionally the role of NF-κB in muscle atrophy has been 
demonstrated by its capability of controlling the expression of MuRF1. Cai et al. (Cai et al., 
2004) demonstrated that the activation of NF-κB in muscle-specific transgenic mice activated  
IKK (MIKK) and induces significant atrophy due to an accelerated protein breakdown, which 
is mediated by the expression of MuRF1. 
1.2.2.4 Apoptosis 
Apoptosis is an extremely organized process of programed cell death that can happen both in 
physiological and pathological conditions (Marzetti et al., 2012; Otrocka-Domagala, 2011). 
The main role of apoptosis is to reduce the number of cells in excessive proliferation and to 
eliminate damaged or metabolically broken cells. Apoptosis can be activated by both external 
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and internal signals in the cell, triggering a number of molecular pathways of cell death 
(Marzetti et al., 2012). The apoptotic machinery includes regulatory proteins, endonucleases, 
protease inhibitors, and proteolytic enzymes, known as caspases. Upon stimulus for cell 
death, initiator caspases (caspases 8, 9, and 12) are activated which in turn leads to activation 
of effector caspases (caspases 3, 6, and 7) that regulates the cellular degradation and DNA 
fragmentation (Carmeli et al., 2015). In addition, apoptotic signaling in skeletal muscles can 




Figure 2. Muscle mass regulating signaling pathways.  
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1.3 MUSCLE SPECIFIC DIFFERENCES 
Skeletal muscles are heterogeneous both at the level of whole muscles, motor units and 
individual muscle fibers. Different muscle properties will decide the specific movements that 
each muscle can perform. An important aspect of muscle diversity lies in their embryological 
origin (Merrell and Kardon, 2013; Sambasivan et al., 2009). Craniofacial muscles, are 
evolutionarily and developmentally distinct from trunk and limb muscles (Noden and 
Francis-West, 2006; Sambasivan et al., 2011). Trunk and limbs muscle are derived from 
somites that originate from the paraxial mesoderm of the trunk, whereas the cranial 
mesoderm gives rise to head muscles like extraocular muscles and cheek muscles like the 
masseter and the buccinators (Grifone and Kelly, 2007; Harel et al., 2009; Nathan et al., 
2008). MyoD, Myf5 and Mrf4 are myogenic regulatory factors that work together to control 
the entry to the myogenic differentiation program and that applies to all skeletal muscles. 
However, the regulatory hierarchies that act upstream of the myogenic factors are diverse in 
somatic and cranial mesoderm (Czajkowski et al., 2014). Significant differences between 
muscles also lies in further development into mature skeletal muscles (Merrell and Kardon, 
2013).  
In adult skeletal muscles and muscle fibers, the same stimulus can cause drastic divergent 
responses. The same fiber type may undergo opposite changes in different muscles. Even 
within the same muscle different fiber types react differently (Blaauw et al., 2013; Schiaffino 
et al., 2013). The nervous system utilizes the capacity of the muscles to generate force and 
movement for a variety of motor tasks. These tasks can roughly be divided into three main 
types; postural joint stabilization, long lasting repetitive activities (like respiration) and fast 
and powerful actions (such as jumping or kicking). In mammals the motor units are 
functionally organized into separate components, the motor units each consist of a 
motoneuron and the muscle fibers that it exclusively innervates. Muscle fibers attain a degree 
of specialized molecular structure and physiological parameters to perfectly suit the needs of 
the motor units (Blaauw et al., 2013). The heterogeneity of skeletal muscle fibers, therefore, 
mainly reflects an adaptation to the different patterns of activity; in addition it also indicates 
specialization in membrane properties, calcium shuttling mechanisms, contractile machinery 
and the structure of the cytoskeleton (Polla et al., 2004; Schiaffino and Reggiani, 2011).  
The diaphragm is a muscle engaged in a nonstop rhythmic activity which does not permit any 
break to rest. Therefore the diaphragm muscle fibers must be very resistant to fatigue (Merrell 
and Kardon, 2013; Polla et al., 2004). In addition to ventilation, the diaphragm muscle is also 
required for coughing, talking and singing, activities which are phasic and occasional. 
Diaphragm fibers generally have a smaller CSA than limb muscles. However the number of 
capillary vessels surrounding each fiber is the same, the diffusion distance is reduced which 
makes the oxygen supply more efficient in the diaphragm than in other muscles. This might 
improve oxygen diffusion and contribute to the increased resistance of the diaphragm to 
fatigue. Respiratory muscle fibers do not undergo the same changes in response to training 
and inactivity as limb muscle fibers (Merrell and Kardon, 2013; Polla et al., 2004).  
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1.4 MUSCLE WASTING IN THE INTESIVE CARE UNIT 
Acquired muscle weaknesses in the intensive care unit (ICU) is a major complication that 
occurs in severely ill patients and has a significant impact on the immune system, energy 
metabolism, amino acid reserves, and temperature regulation (Puthucheary et al., 2010b). It 
affects the limb and respiratory muscles, and, as a consequence it usually complicates 
weaning from the ventilator, increases the length of stay in the intensive care unit, and 
prolongs physical rehabilitation. This condition can either affect the peripheral nerves (critical 
illness polyneuropathy, CIP), skeletal muscles (critical illness myopathy, CIM) or both 
(critical illness polyneuromyopathy, CIPNM) (Latronico and Bolton, 2011; Latronico and 
Guarneri, 2008; Visser, 2006). CIP and CIM are the primary cause of muscle weakness and 
paralysis in the ICU (Latronico and Bolton, 2011). The prevalence of CIP and CIM in the 
general ICU population is currently unknown (Tennila et al., 2000; Zink et al., 2009), 
however, in subpopulations in which sepsis is complicated by multiple organ failure, the 
incidence of CIP and/or CIM could even reach 80-100% (Tennila et al., 2000). The weakness 
seems to be caused by critical illness and the ICU course regardless of the underlying primary 
condition (Lacomis et al., 1996; Maramattom et al., 2004). Muscle wasting and weakness is 
increasingly being recognized and the increasing prevalence of diagnosed ICU acquired 
weakness is both due to a growing awareness and improved survival of patients with 
prolonged organ failure (Puthucheary et al., 2010b). Muscle atrophy occurs within 10 to 21 
days of muscle disuse when healthy older adults are bound to bedrest. Similar adverse 
skeletal muscle changes happen as early as days 5 to 7 after ICU admission in critical ill 
patients (Puthucheary et al., 2010b).   
1.4.1 Critical illness myopathy  
CIM is a myopathy that results from critical illness and is commonly found in deeply sedated 
immobilized and mechanically ventilated ICU patients. MacFarlane and Rosenthal were the 
ones to describe CIM, almost 40 years ago (MacFarlane and Rosenthal, 1977). The illness is 
characterized by paralysis of the limb muscles, apparent atrophy of the skeletal muscles and 
reduced muscle excitability but with intact nerve conduction velocities (Larsson et al., 2000; 
MacFarlane and Rosenthal, 1977). A unique feature of CIM is a specific myosin filament 
loss, which leads to muscle mass wasting and loss of function (Larsson et al., 2000; Sander et 
al., 2002). Other key findings are decreased generation of muscle force and unbalanced 
muscle metabolism, disorganization of sarcomeres, altered protein turnover and impaired 
autophagy (Friedrich et al., 2015). Among critically ill adults, CIM is linked to prolonged 
mechanical ventilation (MV), persistent functional disability, loss of independence, and 
decreased life expectancy.  
Systemic factors cause muscle damage and intracellular signals alter bioenergetics and 
increases muscle protein break-down. Even though the development of muscle impairment 
associated with CIM is being described with increasing accuracy as a result of advances in 
genetic and proteomic science, the exact cause and underlying mechanisms of the disease 
remain unknown.  
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Many triggering factor have been suggested for CIM and muscle wasting in the ICU 
including sepsis, systemic inflammatory response syndrome (SIRS) and multiple organ 
failure. Animal models have, however, allowed the separation of sepsis and other 
confounding risk factors, e.g., mechanical ventilation and muscle unloading, which are 
usually present in ICU patients. Sepsis on its own has then not been able to replicate the CIM 
phenotype (Friedrich et al., 2015). Other potential triggering factors evolve from the 
interventions used in modern anesthesiology and the ICU, that is; prolonged mechanical 
ventilation, neuromuscular blockers (NMB), systemic corticosteroid (CS), hormone treatment 
and muscle unloading (Larsson, 2007).  
1.4.2 Ventilator-induced diaphragm dysfunction 
MV is often a life-saving procedure for patients with respiratory failure, however, there is 
increasing suggestion that prolonged disuse of the diaphragm results in rapid development of 
diaphragmatic weakness due to both atrophy and contractile dysfunction. This harmful effect 
of prolonged MV has been named ventilator-induced diaphragmatic dysfunction (VIDD) 
(Powers et al., 2013; Vassilakopoulos and Petrof, 2004). Most patients are without difficulty 
removed from MV, but about 25% of patients experience difficult weaning (Daniel Martin et 
al., 2013). Furthermore, for these patients, weaning procedures account for 40% - 60% of the 
total time on the ventilator (Esteban et al., 1994; Esteban et al., 1995). There is still little 
information available regarding the underlying mechanism in humans. By using both 
microscopic and molecular analyses of diaphragm tissue, it has been shown that VIDD 
induces significant decreases in fiber cross-section and a substantial up-regulation of 
oxidative stress enzymes and activation of several intracellular proteolytic pathways 
including the UPS (Levine et al., 2008; Petrof et al., 2010; Shanely et al., 2002). 
1.4.3 Preventive and therapeutic approaches 
Some therapeutic strategies have been proposed for the prevention of CIM and muscle 
wasting in the ICU, including nutritional interventions, antioxidant therapy, application of 
testosterone derivatives and growth hormones (Garnacho-Montero et al., 2001; Hermans et 
al., 2014; Hermans et al., 2009). However, none of these interventions has conclusively 
shown to have beneficial effects on muscle function (Zink et al., 2009). Strategies used today 
to inhibit muscle weaknesses and wasting in the ICU, mainly focus on avoiding and reducing 
risk factors, like sepsis, hyperglycemia, prolonged immobilization, prolonged duration of 
mechanical ventilation as well as the use of corticosteroids and neuromuscular blocking 
agents (Hermans et al., 2014; Zink et al., 2009). Additionally, strategies that prevent the 
catabolic state associated with critical illness are now being used and could be beneficial. 
Thus, therapeutic strategies are evidently limited and with uncertain beneficial effects, further 
research is clearly needed to achieve a better understanding of the cellular and molecular 
mechanisms underlying the muscle wasting and weakness seen in ICU patients.
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2 AIM 
The aim of this thesis is to achieve a better understanding of the cellular and molecular 
mechanisms underlying the muscle wasting and weakness seen in ICU patients with CIM. 
The objective is to evaluate specific therapeutic strategies and efficient rehabilitation 
programs. In accordance with the stated objectives, a rodent ICU model was used to address 
the mechanistic and therapeutic aspects of the disease. The long term goal of this project is to 
unravel underlying mechanisms, identify new therapeutic strategies and efficient 
rehabilitation programs. 
2.1 SPECIFIC AIMS 
 Determine the effects of passive mechanical loading on mucle wasting in response to 
mechanical silencing in an experimental rat ICU model (Paper I). 
 Gain insight into the molecular pathways regulating the process of mechanical 
activation of skeletal muscles that are affected by the ICU condition (Paper II). 
 Follow the time course changes of the diaphragm muscle structure and function, as 
well as gene and protein levels affected by the ICU condition. 
 Gain understanding of mechanisms of the relative sparing of a cranial nerve 
innervated muscle in response to mechanical silencing, in comparison to spinal nerve 
innervated muscles. 
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3 METHODS 
3.1 ANIMALS 
Female Sprague-Dawley rats were anaesthetized, treated with α-cobra toxin and mechanically 
ventilated for durations varying from 6 hours to 14 days. The sham-operated control animals 
underwent the same interventions as the controls, but were not pharmacologically paralyzed 
with α-cobra toxin, that is, sham operated controls were anaesthetized (isoflurane), 
spontaneously breathing, given intra-arterial and intravenous solutions, and euthanized within 
2 hours after the initial anesthesia and surgery. Animals were euthanized by removing the 
heart during deep isoflurane anesthesia and controlled mechanical ventilation.  
 
3.2 MECHANICAL LOADING 
The mechanisms underlying the effects on skeletal muscle structure and function by passive 
mechanical loading in animals exposed to immobilization and mechanical ventilation (“ICU 
intervention”) was investigated. The left leg of the animal was activated for 6 hours at the 
shortest duration and 12 hours day −1 at durations 12 hours and longer throughout the 
experiment, using a mechanical lever arm that produced continuous passive maximal ankle 
joint flexions–extensions at a speed of 13.3 cycles min −1 (Paper I and II). Experiments were 
terminated at durations varying between 6 hours and 14 days 
 
3.3 MUSCLE BIOPSIES AND PERMEABILIZATION OF MUSCLE FIBER 
MEMBRANE  
The EDL, soleus, plantaris and the gastrocnemius muscles from the loaded left leg and the 
unloaded right leg (Paper I and II), the masseter (Paper III) and the diaphragm (Paper IV), 
were dissected immediately after the animals were killed. The masseter, plantaris and the 
gastrocnemius muscle and one half of the diaphragm, EDL and soleus muscle was quickly 
frozen in liquid propane cooled by liquid nitrogen and stored at -160°C for further analyses. 
The other half of the diaphragm, EDL and soleus muscle were placed in relaxing solution at 
4°C and bundles of ~50 fibers were dissected free and tied with surgical silk to glass capillary 
tubes at slightly stretched lengths. The bundles were then treated with skinning solution 
(relaxing solution containing glycerol; 50:50 v/v) for 24 hours at 4°C, after which they were 
transferred to -20°C. The muscle bundles were treated with sucrose, a cryo-protectant, within 
1-2 weeks for long-term storage (Frontera and Larsson, 1997). Subsequently, the muscle 
bundles were detached from the capillary tubes and snap frozen in liquid nitrogen-chilled 
propane and stored at -160°C. One day before the experiments, a bundle was transferred to a 
2.0 M sucrose solution for 30 min, then incubated in solutions of decreasing sucrose 
concentration (1.5-0.5 M) and finally kept in a skinning solution at -20°C. 
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3.4 PROTEIN EXPRESSION ANALYSIS 
3.4.1 Total protein content  
Total protein content was determined from 10μm EDL, soleus (Paper I and II), 
gastrocnemius, plantaris (Paper II), diaphragm (Paper III) and masseter (Paper IV) muscle 
cross-sections dissolved in 100μl 8M urea buffer after centrifugation and heating (90°C for 2 
min) using the NanoOrange® protein quantification kit (Paper I) and the Pierce® 660 
protein assay (Paper II and IV) according to manufactures instructions.   
3.4.2 Myosin and actin content 
Myosin and actin contents were quantified on 12% SDS-PAGE (Paper I). The total 
acrylamide concentration was 4% (w/v) in the stacking gel, 12% in the running gel and the 
gel matrix included 10% glycerol. Samples were loaded together with the standard dilutions. 
The standard was prepared by pooling sections from control rat EDL and soleus muscles. The 
myofibrillar protein standards were prepared, assuming that actin and myosin contents were 
12.5 and 25% of the total protein content, respectively. Linear actin and myosin curves were 
observed within the 5-200 μg ml −1 range, but the calibration curves were not parallel. Gel 
electrophoresis was performed at a constant current of 16 mA for 5 hours at 15°C. The gels 
were stained with coomassie blue and subsequently scanned in a soft laser densitometer. The 
volume integration function was used to quantify the amount of protein.  
3.4.3 Myosin and actin ratio 
Myosin and actin ratios were measured on 12% SDS-PAGE (paper I and IV). The total 
acrylamide concentration was 4% (w/v) in the stacking gel, 12% in the running gel and the 
gel matrix included 10% glycerol. Gel electrophoresis was performed at a constant current of 
16 mA for 5 hours at 15°C. The gels were stained with coomassie blue and subsequently 
scanned in a soft laser densitometer. The volume integration function was used to quantify 
myosin and actin. 
3.4.4 Myosin heavy chain isoform expression 
MyHC isoform expression was determined by 6% SDS-PAGE (Paper I and IV). The total 
acrylamide concentration was 4% (w/v) in the stacking gel, 6% in the running gel, the gel 
matrix included 30% glycerol. The gel electrophoresis was performed at a constant voltage of 
120 V for 20-22 hours at 10°C. The gels were silver-stained and subsequently scanned in a 
soft laser densitometer.  
3.4.5 Troponin isoform expression  
Troponin (Tn) isoform expression was measured in TA muscle samples homogenized in 
SDS-gel sample buffer (Paper I). After heating (5 min at 80°C) and centrifuging muscle 
samples were stored at -80°C. For SDS-PAGE the protein extracts were resolved on 14% 
Laemmli gel with an acrylamide/bis ratio of 180:1. The protein bands were visualized by 
staining the gel with Coomassie Brilliant Blue R250.  
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3.4.6 Western blots 
To study the expression of specific proteins, immunoblot analysis were done. In paper I 
troponin isoform expression was measured in TA muscle. Atrogin-1 and MuRF1 was 
measured in the soleus and Grp94 protein levels were studied in the plantaris muscle. In 
paper II S6, P-S6 (Ser240/244), 4EBP1, P-4EBP1 (Thr37/46), Akt, P-Akt (Ser473) was 
measured in soleus and in plantaris muscles. Caspase 3 was measured in the gastrocnemius 
muscle. Additionally AIF and cytochrome C was quantified in the cytosolic and 
mitochondrial fraction of the gastrocnemius muscle. In Paper III MuRF1, Grp94, Caspase 3, 
Calpain and LC3B protein levels were studied in the diaphragm muscle. In paper IV atrogin-
1, MuRF1, Akt, P-Akt (Ser473), LC3B, HSP70, HSP90, β-crystallin, MMP-2 and TIMP-2 
were quantified in the masseter muscle. The immunoblots were subsequently scanned in a 
soft laser densitometer, the signal intensities were quantified using the volume integration 
function (arbitrary units) and normalized to actin, actinin or complex IV.  
3.4.6.1 Protein Carbonylation Levels  
To assess the formation of protein carbonyl groups, the OxyBlot protein oxidation detection 
kit (Chemicon, Chandlers Ford, UK) (Paper I and III) was used. About 12μg of total protein 
was used for derivatization with 2.4-dinitrophenylhydrazine (DNPH) according to the 
manufacturer’s detailed protocol and processed for Western blot analysis. A positive control 
included derivatization of 3μg of oxidized bovine serum albumin (BSA), whereas the 
negative control was performed with an equal amount of total protein reacted in the absence 
of DNPH. Levels of oxidated protein were quantified using the NIH Image J analysis 
software. 
 
3.5 GENE EXPRESSION ANALYSIS 
3.5.1 Total RNA isolation and quantification 
Total RNA was extracted from frozen gastrocnemius muscle (proximal part) (Paper I and 
II), plantaris muscle (Paper II), diaphragm (Paper III) and masseter (Paper IV) tissue (10-
30 mg) using a Qiagen RNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA). RNA 
concentrations were then quantified using the fluorescent nucleic acid stain Ribogreen 
(Molecular Probes, Eugene, OR, USA), on a fluorescence spectrophotometer. 
3.5.2 Real time Polymerase chain reaction (qPCR) 
qPCR was used to analyze mRNA levels for MyHC isoforms (Paper I, III and IV), actin 
(Paper III and IV), MuRF1, atrogin-1 (Paper II and IV), IGF-1, Fbxo 31, SMART, Mgn, 
HDAC4, HDAC5, PGC-1α, PGC-1α4, Fis1, OPA1, Mfn1, Mnf2, Bnip3, Pink1, Parkin 
(Paper II). cDNA synthesis and qPCR was performed as described in the papers I, II, III and 
IV.  
 26 
3.5.3 Gene expression profiling (Paper I) 
Three micrograms of total RNA from the proximal gastrocnemius muscle samples was 
extracted and processed to generate biotin-labelled cDNA. Each sample was then hybridized 
to an Affymetrix Rat Gene 1.0 ST Array. Microarray data were background-adjusted, 
normalized and log transformed summarized values. In order to search for the differentially 
expressed genes between the samples from the different days an empirical Bayes moderated 
t-test was applied. A linear model was fitted to the data, controls vs unloaded and unloaded vs 
loaded at the following time durations: 0.25-4 days, 5-8 days and 9-14 days. To address the 
problem with multiple testing, the p-values were adjusted according to Benjamini and 
Hochberg. Probe sets with a minimum fold change of ±1.5 and adjusted p-value < 0.5 at least 
in one of the time points were included for further analysis.  
 
3.6 IMMUNOHISTOCHEMISTRY (PAPER III) 
3.6.1 Immunohistochemistry nNOS 
After a 10 min fixation at room temperature with 4% buffered paraformaldehyde, 
cryosections were incubated overnight at 4°C with anti-neuronal nitric oxide synthase (anti-
nNOS) antibody, extensively rinsed with PBS and incubated for 2 h at room temperature with 
secondary antibody conjugated with Alexa 568. Slides were observed with a Leica SP5 
confocal microscope equipped with a helium 543 nm laser (Leica Microsystems). 
3.6.2 MyHC immunohistochemistry 
Serial consecutive transverse cryosections of, diaphragm muscle, were assayed for 
immunohistochemistry using anti-MyHC antibodies. The following antibodies were used: 
clone BA-D5 for type I-β MyHC, clone SC-71 for type IIa MyHC, and clone BF-35, which 
labels all MyHCs except for type IIx, and therefore allows the identification of the unreacting 
myofiber as type IIx. 
3.6.3 DNPH immunohistochemistry 
Serial cryosections labelled with anti-myosin antibodies were reacted with DNPH for 1 hour 
at room temperature (Vitadello et al., 2003). After a 10 min rinse, sections were saturated 
with 3% BSA for 20 min, and incubated with the anti-DNPH antibody. Bound antibody was 
revealed by peroxidase immunohistochemistry. 
3.6.4 NADPH-d histochemistry 
Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity was 
demonstrated by histochemistry. Cryosections were fixed for 10 min, after rinsing with PBS, 
sections were incubated in medium containing Tris-HCl, Triton X-100, nitroblue tetrazolium 
chloride and NADPH for 45 min at 37°C. Reaction was stopped by rinsing briefly with 
distilled water. Consistency of the labelling was validated by independent analysis of adjacent 
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cryosections. Histochemical and immunohistochemical analysis was performed using the 
Zeiss Axioplan microscope and ×10 and ×40 Plan-Neofluar objectives. Images were acquired 
using a Leica digital DFC 300FX camera and the IM50 software. Myofiber cross-sectional 
circumference (CSC) was evaluated using ImageJ software.  
3.7 CONTRACTILE MEASURMENTS OF SINGLE MUSCLE FIBERS 
On the day of an experiment, a fiber segment 1-2 mm long was left exposed to the 
experimental solution between connectors leading to a force transducer and a lever arm 
system (Paper I and III). The apparatus was mounted on the stage of an inverted 
microscope. While the fiber segments were in relaxing solution, the sarcomere length was set 
to 2.65-2.75 μm by adjusting the overall segment length. The diameter of the fiber segment 
between the connectors was measured through the microscope at a magnification of ×320 
with an image analysis system prior to the mechanical experiments. Fiber depth was 
measured by recording the vertical displacement of the microscope nosepiece while focusing 
on the top and bottom surfaces of the fiber. The focusing control of the microscope was used 
as a micrometer. Fiber CSA was calculated from the diameter and depth, assuming an 
elliptical circumference, and was corrected for the 20% swelling that is known to occur 
during skinning. Maximum active tension (P0) was calculated as the difference between the 
total tension in the activating solution (pCa 4.5) and the resting tension measured in the same 
segment while in the relaxing solution. All contractile measurements were carried out at15°C. 
Specific force (SF) was calculated as maximum tension (P0) normalized to CSA. After the 
mechanical measurements, each fiber was placed in urea buffer and stored at -80°C for 
subsequent electrophoretic analyses. 
3.8 FRACTIONAL PROTEIN SYNTHESIS RATE (PAPER I) 
Fractional protein synthesis rate was used to measure the rate of muscle protein synthesis in 
the superficial and deep part of the gastrocnemius muscle using [ring-13C6] phenylalanine 
(15μg g−1 body weight) as a tracer. The level of enrichment of [ring-13C6] phenylalanine in 
the tissue was analyzed using chromatography tandem mass spectrometry (GC/MS/MS).  
3.9 MASS SPECTROMETRY (PAPER III) 
LC/MS analysis of myosin heavy chain isoforms was performed to investigate post 
translational modifications of myosin 
3.9.1 In-gel digestion  
The type I, IIa, IIx and, in some instances, IIb, MyHC isoforms were separated on a 6% SDS-
PAGE gel. The bands were cut out and washed with 100 mM NH4HCO3 and then reduced. 
The samples were alkylated and then dried at 50°C before treating with trypsin and then kept 
at 37°C overnight. Samples were sonicated, on the following morning and the liquid was 
collected and then dried under vacuum. The peptides were stored at -20°C until further 
analysis. 
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3.9.2 Liquid chromatography (LC)/mass spectrometry (MS) analysis 
The LC/MS analysis was performed using the linear ion trap. The precursor ions were 
isolated within a 1Da window and fragmented by collision-induced dissociation with 35% 
normalized collision energy. The activation time was set to 10 ms and q =0.25. Dynamic 
exclusion was set to 30 s and the exclusion mass width was set to 5 p.p.m. relative to the 
reference mass.  
3.10 X-RAY DIFFRACTION (PAPER III) 
Structural analysis of diaphragm bundles was assessed by x-ray diffraction. On the day of x-
ray recordings, fiber bundles were placed in a plastic dish containing a relaxing solution and 
washed thoroughly to remove the glycerol. They were then transferred to a specimen 
chamber filled with the same relaxing solution. Each fiber bundle was then fixed (clamped 
ends) and slightly stretched. Subsequently, X-ray diffraction patterns were recorded at 15°C. 
For each fiber bundle, approximately 20–40 diffraction patterns were recorded at the 
BL45XU beamline of Spring-8.  
3.11 STATISTICS 
Sigmaplot software (systat Software, Inc., CA, USA) was used to generate descriptive 
statistics. Means, standard error of the means (SEM) and linear regression analysis were 
calculated according to standard procedures. Paired t-test in pairwise comparison, between 
the loaded and unloaded One and Two-way analysis of variance (ANOVA) and the Tukey 
post-hoc test were used when comparing multiple groups. When normality test failed, a one 
way ANOVA on ranks, i.e., Kruskal-wallis and the Dunn’s post-hoc were performed. 
Differences were considered significant at p < 0.05. 
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4 RESULT AND DISCUSSION 
4.1 BENEFICIAL EFFECTS OF PASSIVE MECHANICAL LOADING ON 
SKELETAL MUSCLES (I) 
Mechanical silencing (absence of external and internal strain) has been shown to be a key 
factor underlying muscle wasting associated with the ICU condition (Ochala et al., 2011a). 
Hence it was hypothesized that passive loading would alleviate the muscle wasting and 
decreased force-generation capacity associated with CIM and mechanical silencing. A 
physical therapy intervention was consequently tried using a rat ICU model. Animals were 
subjected to unilateral passive mechanical loading for 12 hours per day for up to 14 days. 
Results showed a significant decrease in muscle atrophy associated with the ICU condition, 
independent of muscle type. At the single fiber level, a 44% higher CSA and a doubling of 
the force generating capacity was observed. This was accompanied by an up-regulation of 
transcriptional levels of contractile proteins from 5-8 days of the ICU intervention, thus 
leading to a reduced myosin loss in the soleus. This is in accordance with other studies that 
have shown that static passive stretching suppresses muscle wasting associated with 
denervation, hind-limb suspension and cast immobilization (Agata et al., 2009; Coutinho et 
al., 2004; Sasa et al., 2004; Williams, 1990).  
The beneficial effects of passive mechanical loading on alleviating the muscle atrophy in 
sedated pharmacologically paralyzed and mechanically ventilated rats support the importance 
of early physical mobility therapy in deeply sedated and mechanically ventilated ICU 
patients, resulting in shortening of ventilator days and ICU stay. This also reduces the 
financial costs and enhances patients prognosis and the quality of life of survivors 
(Brahmbhatt et al., 2010; Morris, 2007; Morris et al., 2008; Needham et al., 2010; 
Schweickert et al., 2009).  
 
4.2 MYOSTATIN-SMAD2/SMAD3 PATHWAY MAY BE INVOLVED IN THE 
BENEFICIAL EFFECTS OF PASSIVE MECHANICAL LOADING  
Caveolin-3 (Cav3) is a muscle specific, membrane protein that directly binds to and regulates 
specific lipid and lipid-modified proteins (Ohsawa et al., 2008). Several mutations in the 
Cav3 gene have been detected in autosomal dominant limb-girdle muscular dystrophy and 
autosomal dominant rippling muscle disease (Betz et al., 2001; Galbiati et al., 1999; Minetti 
et al., 1998). Further, it has also been shown that Cav3 is an inhibitor of Mstn that works by 
suppressing Mstn’s intracellular signaling to phosphorylate Smad2, inter alia (Ohsawa et al., 
2008).  
Follistatin (Fstn), is a protein which has been found to inhibit TGF-β family members (Lee, 
2010). Specifically Fstn has been shown to function as a potent inhibitor of Mstn both in 
vitro and in vivo (Lee and McPherron, 2001; Zimmers et al., 2002). 
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Both Cav3 and Fstn were consequently up-regulated after 5 days of ICU intervention in 
response to passive mechanical loading. This suggests a stimulation of muscle growth 
through the mysotatin/Smad2/Smad3 pathway, and possible by prompting protein synthesis 
by Akt and mTORC1 (Amirouche et al., 2009; Lagirand-Cantaloube et al., 2008; Lokireddy 
et al., 2011; Sartori and Sandri, 2015; Trendelenburg et al., 2009). 
However, further investigation is needed to resolve how passive mechanical loading causes 
the up-regulation of Cav3 and Fstn to stimulate muscle growth through the 
mysotatin/Smad2/Smad3 pathway.  
 
4.3 MITOCHONDRIAL DYNAMICS PLAY A CRITICAL ROLE IN THE 
BENEFICIAL EFFECTS OF PASSIVE MECHANICAL LOADING (II) 
Mitochondria are constantly changing in number, shape and localization. This feature is a 
result of the continuous alteration between fusion and fission events. Mitochondrial dynamics 
are important to secure proper mitochondria maintenance and repair. Alteration of the 
mitochondrial morphology allows exchange of mitochondrial content and discrimination of 
terminally damaged mitochondria to enable degradation by a controlled autophagy called 
mitophagy (Chen and Chan, 2010; Tondera et al., 2009). Alterations in mitochondria 
functions have long been characterized in different conditions of muscle wasting such as 
aging, diabetes and muscular dystrophies (Bernardi and Bonaldo, 2008; Larsson, 2010; 
Mootha et al., 2004; Patti et al., 2003). Furthermore, it was similarly shown that an imbalance 
in mitochondrial dynamics plays a role in the development of muscle atrophy induced by 
denervation, fasting and FoxO3 overexpression (Romanello et al., 2010b). In accordance with 
these results we found alterations in mitochondrial dynamics in response to mechanical 
silencing associated with CIM in the experimental ICU rat model. Transcription levels of 
Fis1, Opa1, Mfn1 and Mfn2, all mediators of mitochondrial fission and fusion, were 
significantly up-regulated after 5 days of mechanical silencing and remained up-regulated 
after 9-14 days. This up-regulation was however restricted to the unloaded side, i.e. on the 
loaded side these transcripts remained at control levels (Figure 3).  
Additionally, Bnip3, Pink1 and Parkin were analyzed to study the effect of the ICU treatment 
and passive mechanical loading on mitophagy. Significant changes at the transcriptional 
levels of Pink1 were observed between the loaded and the unloaded side both after 5-8 days 
and 9-14 days. Similarly, Parkin was significantly induced after 5 days and passive 
mechanical loading counteracted this induction (Figure 3).  
Consequently, this indicates a key role of mitochondrial dynamic events as well as mitophagy 
in muscle wasting induced by mechanical silencing associated with ICU treatment and CIM, 
furthermore, these effects were completely counteracted by passive mechanical loading. 
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Figure 3. Mitochondria dynamics and Mitophagy 
Transcription levels of Fis1, OPA1, Mfn1 mfn2, BNIP3, Parkin and Pink1 in plantaris muscle from control 
animals and from animals exposed to sedation, NMB, mechanical ventilation and unilateral passive mechanical 
loading for 0.25-4, 5-8, 9-14 days. Values are fold changes over controls and are means +SEM and Significant 
differences are indicated by * p< 0.05, ** p<0.01, *** p< 0.001 
 
4.4 A NOVEL SET OF UBIQUITIN LIGASES ARE INDUCED BY MECHANICAL 
SILENCING (II) 
Milan et al. (Milan et al., 2015) recently demonstrated that specific deletion of FoxOs in 
skeletal muscles prevents muscle loss and force decline in response to fasting and 
denervation. It was demonstrated that the FoxO family is required for the induction of several 
atrogenes including a set of novel E3s. A novel gene that encodes an F-box protein (FbxO21) 
was identified and given the name SMART, however its substrates are still unknown. In 
accordance with this, SMART and FbxO30 was up-regulated in response to mechanical 
silencing after 5-8 days of ICU intervention in the rat model. Transcriptional levels of both 
these E3 ligases also remained elevated after 9-14 days. Additionally, the up-regulation of 
these E3s was only observed on the unloaded side, on the loaded side, the transcriptional 
levels did not differ from controls. This suggests that mechanosensing plays a more important 
role than motoneuron discharge pattern in regulating the expression of these E3 ligases.  
Gain- and loss-of-function experiments also showed that FoxOs are required for SMART 
regulation and that FoxO1 and FoxO3 are recruited on the promoter. Deletion of FoxO3 and 
not of FoxO1, however, completely blunted SMART induction after denervation (Milan et 
al., 2015) suggesting that SMART is mainly under FoxO3 regulation and that FoxO3 may 
play a significant role in disuse muscle wasting.  
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4.5 CONTROLLED MECHANICAL VENTILATION CAUSES EARLY 
CONTRACTILE DYSFUNCTIONS IN THE DIAPHRAGM (III) 
Controlled mechanical ventilation (CMV) plays a key role in triggering the impaired 
diaphragm muscle function and the concomitant delayed weaning from the respirator in 
critically ill ICU patients (named VIDD). Experimental and clinical studies done in order to 
investigate the effect on diaphragm by CMV have mainly focused on early effects (Gayan-
Ramirez et al., 2003; Racz et al., 2003) or at specific time points (De Jonghe et al., 2007; 
Radell et al., 2002; Yang et al., 2002).  
A time-resolved analyses was performed, ranging from 6 hours to14 days using an 
experimental rat ICU model allowing detailed studies of the diaphragm in response to long-
term CMV to improve our understanding of the mechanisms underlying VIDD. In 
accordance with former studies a rapid and early decline in maximum muscle fiber force was 
seen. However, on the contrary to previous studies that have shown a severe atrophy in 
response to short durations of CMV (De Jonghe et al., 2007; Gayan-Ramirez et al., 2003; 
Racz et al., 2003), muscle fiber size was maintained for the initial 4 days of mechanical 
ventilation in our model. Further these results are in accordance with previous observation 
seen in an experimental pig model, where no decrease in CSA was seen in response to CMV 
for 5 days (Ochala et al., 2011b). The combined effects of mechanical ventilation on fiber 
size and SF indicated a 25, 64 and 85% reduction of diaphragm muscle function in response 
to 0.25-4, 5-8 and 9-14 days of CMV compared with control fibers, respectively. The 
disagreement between the results may be due to other confounding factor, besides MV when 
commercially available ventilators are used even at duration’s shorter than 24 hours (Larsson 
et al., 2015). 
 
4.6 DIAPHRAGM ATROPHY, IN RESPONSE TO UNLOADING, DIFFERS FROM 
UNLOADED INDUCED ATROPHY IN THE LIMB MUSCLES (III) 
The atrophy and loss of SF observed in the diaphragm, in response to CMV in this study, was 
more severe than what previously has been observed in limb muscles of animals exposed to 
the same type of intervention (Ochala et al., 2011a). In this study myosin:actin ratios 
remained unchanged until 9-14 days of CMV which is a significant difference from what has 
been observed in the limb muscles where myosin:actin ratios are reduced after 5 days of the 
ICU intervention. A decrease of myosin content was observed over time, hence indicating 
that protein degradation is not specific to myosin, but is also affecting actin, in the diaphragm 
muscle. This is in accordance with another study that demonstrated that myosin and actin 
degradation occurs in the diaphragm following 18-72 hours of CMV in brain dead, organ 
donors (Levine et al., 2011). On the other hand transcriptional levels of both myosin and actin 
remained unchanged until 9-14 days of exposure to CMV also in sharp contrast to what has 
been observed in the limb muscles, where the transcriptional levels of myosin and actin were 
dramatically decreased (Ochala et al., 2011a). Collectively these results demonstrate a 
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significant difference in the transcriptional regulation of contractile proteins between the 
diaphragm and limb muscles.  
However, the contractile protein proteolysis does not correlate with the dramatic decrease in 
force generating capacity suggesting that protein degradation alone is not responsible for the 
impaired force production.  
Mechanical ventilation has repeatedly been shown to increase ROS production and induce 
oxidative stress targeting proteins for degradation (Leijten et al., 1995; Powers et al., 2002; 
Shanely et al., 2002; Zergeroglu et al., 2003). In accordance with these studies, an increased 
amount of protein carbonylation was observed in the experimental ICU model. An increasing 
trend was detected early and was significant after 5 days of CMV. Altered ROS levels result 
in mitochondrial dysfunction (Blakemore et al., 1996; Suliman et al., 1999) that can lead to 
apoptosis and activation of the proteasome pathway targeting PTMs induced by oxidative 
stress (Boudriau et al., 1996; Zergeroglu et al., 2003). It has furthermore been shown that 
PTMs can effect muscle fiber function (Prochniewicz et al., 2008; Ramamurthy et al., 2001). 
Using mass spectrometry analyses it was demonstrated that CMV induced myosin PTMs, all 
of which were located in the rod region which is essential for the packing of myosin 
molecules into myosin filaments and for the binding of myosin-associated proteins. 
Unfortunately, less is known about modifications in this region of the myosin molecule than 
in the globular head. Nevertheless, mutation in the rod region of myosin results in specific 
myopathies (Ochala and Larsson, 2012).  
 
4.7 MUSCLE MASS REGULATION MECHANISMS RESPOND DIFFERENT IN 
MASSETER COMPARED TO LIMB AND DIAPHRAGM MUSCLES IN 
RESPONSE TO MECHANICAL SILENCING (IV) 
CIM primarily affects the limb and trunk muscles while cranial nerve innervated muscles are 
spared or less affected. The mechanisms underlying these muscle-specific differences, 
however, remain unknown. Some of the hallmarks of muscle atrophy and CIM, were 
therefore studied, to try to enhance our understanding of the mechanisms of the relative 
sparing of the masseter in response to mechanical silencing.  
It was demonstrated that the 2:1 relationship between myosin and actin content was well 
preserved until the longest duration (9–14 days) in the masseter in contrast to what we 
previously have seen in the limb muscles where myosin:actin ratios  and fiber size show a 
progressive decline after 5 days of the intervention (Ochala et al., 2011a). Furthermore 
transcriptional regulation of myofibrillar proteins in the masseter was not affected by the 
intervention and transcriptional levels of myosin and actin were unaffected during the two 
week observation period. In limb muscles, on the other hand, a dramatic transcriptional 
down-regulation of both myosin and actin was observed at durations longer than five days in 
the same experimental ICU model (Ochala et al., 2011a) as well as in ICU patients with CIM 
(Llano-Diez et al., 2012; Norman et al., 2009). Thus, the cranial nerve innervated masseter 
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muscle seems to resist the atrophy-inducing condition for longer periods than distal hind limb 
muscles.  
In this study, the brief down-regulation of Akt phosphorylation does not seem to affect 
myosin and actin synthesis. Akt also inhibits the activation of FoxO and consequently the up-
regulation of atrogenes, thus protects from protein degradation. The role of Akt was 
confirmed in the masseter as Akt phosphorylation levels were inversely proportional to the 
transcriptional levels of MuRF1 and atrogin-1, as well as to LC3b, which is also regulated by 
FoxO. The significant increase in Akt reactivation in the 9–14 day group may be explained as 
a muscle-specific adaptation to stress.  
 
4.8 MASSETER MUSCLES IMPROVED ANTIOXIDATIVE PROFILE MAY BE 
THE MECHANISM OF PRESERVED MASTICATORY FUNCTION IN CIM (IV) 
Heat shock proteins (HSPs) represent a cellular defense mechanism involved in muscle tissue 
remodeling and adaptation to e.g. oxidation, inflammation or energy changes (Liu and 
Steinacker, 2001). HSPs in the masseter were activated more rapidly than in limb muscles. 
HSP70 increased significantly after 5 days of ICU treatment, while αB-crystallin showed a 
slight but early increase. An up-regulation of HSPs has also been seen in limb muscles in 
response to the ICU intervention (Ochala et al., 2011a), these increases were more delayed 
compared with the masseter. The up-regulation of HSP70 and αB-crystallin and the stability 
of HSP90 protein levels in the masseter accords with our previous cranial-versus-spinal 
response to critical illness in a porcine ICU model, where these three proteins were induced 
to a larger extent in the masseter compared with limb muscles (Aare et al., 2011). 
HSP70 and αB-crystallin also regulate redox signaling of the mitochondria and have an anti-
apoptotic function (Arrigo et al., 2007; Ferrer-Martinez et al., 2006; Parcellier et al., 2005). 
Additionally in one of our porcine critical illness models studies, HSP70 and αB-crystallin 
changes correlated with oxidative stress, in both cranial- and spinal-nerve innervated muscles 
(Aare et al., 2011). Further HSP90 has been shown to be involved in the inflammatory 
signaling via corticosteroid receptors (Dalman et al., 1991; Stephanou et al., 1998). Based on 
previous reports and present observations, we may speculate that mitochondrial oxidation and 
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5 CONCLUSIONS 
 
This thesis has investigated the intracellular pathways controlling the mechanism underlying 
muscle wasting in ICU patients with CIM and the effects of passive mechanical loading in an 
experimental ICU rat model.  
Passive mechanical loading of limb muscles, induces significant positive effects on muscle 
function and is able to attenuate myosin protein loss associated with mechanical silencing and 
CIM. Further, both fission and fusion events as well as mitophagy are significantly affected 
by mechanical signaling. However, mitochondria dynamic alterations induced by mechanical 
silencing are completely counteracted by passive mechanical loading indicating that 
mitochondria may be a key player in the role of mechanosensing. Additionally, the novel 
discovered ubiquitin ligases Fbxo31 and SMART are induced by mechanical silencing, an 
induction that similarly is prevented by passive mechanical loading.  
This demonstrates that the mechanism underlying the effects of passive mechanical loading 
are part of an intricate biological system involving activation and inhibition of different 
protein synthesis- and degradation- pathways, as well as mitochondria function. The 
beneficial effects of passive mechanical loading on muscle structure and function, are 
however, strongly supportive to the use of early physical therapy among immobilized ICU 
patients. 
CMV plays a key role in triggering the impaired diaphragm muscle function in critically ill 
ICU patients. CMV induces early structural changes of the sarcomere that results in impaired 
SF in muscle fibers of the diaphragm. In this study it is demonstrated that CMV induces 
oxidative stress that may further be a key factor triggering post-translational protein 
modifications and the myofibrillar protein disorganization and atrophy. The temporal pattern 
and the lack of preferential myosin loss observed in the diaphragm in response to CMV and 
immobilization differs dramatically to what is occurring in the limb muscles.  
Craniofacial muscles are usually spared or less affected in CIM. Here we demonstrate that the 
masseter muscle sustains a high myosin:actin ratio and muscle fiber size for longer periods of 
exposure to the ICU condition in the experimental rat ICU model. Studying different cell 
signaling pathways it is suggested that an enriched antioxidative profile in the masseter may 
play a role in the mechanisms of preserved masticatory function in CIM.  
Accordingly, these findings demonstrates muscle type differences in the mechanisms behind 
the loss of muscle function associated with the ICU condition between the limb, diaphragm 
and masseter muscles. This important knowledge needs to be taken into account when 
designing strategies for reducing muscle wasting and weakness found in immobilized 
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